Another double-blind placebo-controlled trial of 102 participants with T2DM reported that liraglutide downregulates circulating ceramides, phospholipids, and triglycerides, which further strengthens the recommendation of GLP-1 receptor agonists to prevent cardiovascular disease in T2DM (47). Here, GLP1R is linked to type 2 diabetes mellitus.